TITLE

Health care cost is problem for all; we must solve it

PUB. DATE
November 2004
SOURCE
Automotive News;11/15/2004, Vol. 79 Issue 6121, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article focuses on the problem of the growing cost of health care. It's wrong that some Americans are uninsured or underinsured. And it's wrong that the cost of providing health care coverage for employees has become a major competitive disadvantage for some manufacturers. There are fabulous new drugs and therapies to do things that were miracles a generation ago. That's wonderful, but much of the expense is borne by companies that pay directly for their own employees and indirectly for those people without insurance who must rely on the charity of hospitals. New American manufacturers with young, healthy workers and no retirees might view this as a Big 3 problem that gives them a competitive advantage.
ACCESSION #
15257087

 

Related Articles

  • Drug makers' productivity hurt by steep R&D costs.  // Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p69 

    The article informs that that longer development times for new treatments, the duration of clinical trials and lower success rates have elevated costs in several therapeutic categories in the U.S.

  • Scottish New Medicines Fund doubled.  // PharmacoEconomics & Outcomes News;May2015, Vol. 728 Issue 1, p36 

    The article reports that the Scottish government will increase the amount of New Medicines Fund to be made available for the treatment of end-of-life and rare conditions in 2013-2014.

  • Focus on Biologics Development: Oncobiologics: a case study. Jawadekar, Mak // Contract Pharma;Mar2012, Vol. 14 Issue 2, p42 

    The article presents a case study that examines the cost and duration of clinical studies in the U.S. It mentions the impact of the rising cost of drug development that has forced the pharmaceutical industry to develop business paradigm to reduce the cost of drug development. Moreover, the...

  • Rough Road Ahead for Innovation. WECHSLER, JILL // Pharmaceutical Executive;Jan2016, Vol. 36 Issue 1, p8 

    The article focuses on the factors that hinder innovations in the pharmaceutical industry in the U.S. Discussion of the impact of the rise in total healthcare spending, the increase in prescription drugs expenditures, and the complexities involved in patent applications in the sector is...

  • New generation of drugs may curb health care costs. LIVINGSTON, SHELBY // Business Insurance;5/25/2015, Vol. 49 Issue 11, p0003 

    The article focuses on how biosimilar drugs may help U.S. employers reduce their health care costs. Topics covered include lawsuits filed by biologic drug manufacturers to prevent biosimilars from entering the U.S. market, the use of specialty biologics drugs to treat diseases such as diabetes...

  • Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. Taylor, R. S.; Drummond, M. F.; Salkeld, G.; Sullivan, S. D. // BMJ: British Medical Journal (International Edition);10/23/2004, Vol. 329 Issue 7472, p972 

    Reports on the inclusion of cost effectiveness in licensing requirements of new drugs. How new drugs cannot receive a product license until manufacturers provide evidence of their quality, safety, and efficacy; Details of global drug development; Considerations made by European countries;...

  • Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. Fellows, Garret Kent; Hollis, Aidan // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, p1 

    Background Manufacturers justify the high prices for orphan drugs on the basis that the associated R&D costs must be spread over few patients. The proliferation of these drugs in the last three decades, combined with high prices commonly in excess of $100,000 per patient per year are placing a...

  • Strength In Numbers. Vinas, Tonya // Industry Week/IW;Jan2003, Vol. 252 Issue 1, p57 

    Provides information on the efforts of the manufacturing industry to reduce health-care benefit costs in the U.S. Possible contribution of employer-led coalitions in reducing healthcare costs; Information on negotiations between the National Business Coalition on Health and healthcare...

  • Sound investment. Green, Jeffrey // AHA News;9/18/95, Vol. 31 Issue 38, p7 

    Reports on efforts of hospitals and banks to establish financial-assistance programs to help patients deal with medical expenses. Patient-loan programs; Comments from Richard L. Clarke, president of the Healthcare Financial Management Association.

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics